Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part B International Price Index Could Result In 25% R&D Cuts – Study

Executive Summary

Reductions in research and development spending will be much greater than the 1% average often quoted by HHS, consultant tells the Biotechnology Innovation Organization annual convention.

You may also be interested in...



PhRMA’s Medicare Demos Would Pair Voluntary Price Discounts With Reduced Cost Sharing

Whether an opening gambit for negotiation or the most industry is willing to concede, proposals being offered by industry to replace the Trump Administration’s plan to pursue international reference pricing for Part B drugs seem modest.

What’s Next For The International Pricing Index? Parsing A Strange US Senate Vote

Senate Finance drug pricing bill is moving forward, with two critical amendments defeated by 14-14 tie votes. One would have stripped the inflation penalty from the bill, which probably would have killed any bipartisan momentum. The second targeted the Medicare Part B International Pricing Index and was defeated by a truly surprising set of votes.

For All The Palace Intrigue, Rebate Rule, IPI Go To OMB For Review

For all the rumors of political infighting, the two cornerstones of the Trump administration’s blueprint on drug pricing are in the final phase for review.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS125467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel